Literature DB >> 22427313

Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease.

Kothandam Sivakumar1, Sreeja Pavithran.   

Abstract

Giant coronary artery aneurysms that occur in 0.5 to 1% of patients with Kawasaki disease can be fatal if associated with thrombosis. Some patients may show persistent inflammation and fever despite treatment with repeated doses of intravenous immunoglobulin (IVIG), steroids, and aspirin. This report describes an infant boy with resistant Kawasaki disease who presented with extensive coronary artery involvement and coronary thrombosis. His inflammation was not controlled with multiple doses of IVIG, parenteral and oral steroids, or high-dose aspirin, and he finally needed infliximab, a monoclonal antibody against tumor necrosis factor alpha. The progression of coronary thrombosis was arrested by the platelet glycoprotein 2b/3a receptor blocker, abciximab, during the acute phase of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427313     DOI: 10.1007/s00246-012-0285-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  9 in total

1.  Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.

Authors:  M Mori; T Imagawa; K Yasui; A Kanaya; S Yokota
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

2.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

3.  Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease.

Authors:  H Horigome; T Sekijima; T Miyamoto
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

4.  Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

Authors:  Richard V Williams; Venus M Wilke; Lloyd Y Tani; L LuAnn Minich
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

5.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

6.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients.

Authors:  H Kato; T Sugimura; T Akagi; N Sato; K Hashino; Y Maeno; T Kazue; G Eto; R Yamakawa
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

7.  Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor.

Authors:  Yunku Yeo; TaeYeon Kim; KeeSoo Ha; GiYoung Jang; JungHwa Lee; KwangChul Lee; ChangSung Son; JooWon Lee
Journal:  Eur J Pediatr       Date:  2008-05-14       Impact factor: 3.183

8.  Regression of coronary aneurysms in patients with Kawasaki syndrome.

Authors:  M Takahashi; W Mason; A B Lewis
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

9.  Kawasaki disease: review of risk factors for coronary aneurysms.

Authors:  G Koren; S Lavi; V Rose; R Rowe
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

  9 in total
  2 in total

1.  Kawasaki disease incidence at Chandigarh, North India, during 2009-2014.

Authors:  Surjit Singh; Sagar Bhattad
Journal:  Rheumatol Int       Date:  2016-08-04       Impact factor: 2.631

2.  Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?

Authors:  Shelby Davies; Gabrielle Gold-von Simson
Journal:  Pediatr Cardiol       Date:  2013-06-15       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.